Business
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a clinical and corporate updat
About this update from Pds Biotechnology Corporation
[{"type":"image","alt":"PDS Biotechnology Corporation","displaySize":"","headline":null,"caption":"PDS Biotechnology Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/63fe962c3957c7a225a7c312a7c6913d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6tw_s0aaD8Jse33jriazAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/63fe962c3957c7a225a7c312a7c6913d","width":300,"height":42}},"lazy":false},{"type":"text","content":"VERSATILE-003 Phase 3 Site Initiations Underway","length":47,"tagName":"p"},{"type":"text","content":"Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting","length":109,"tagName":"p"},{"type":"text","content":"Conference call and webcast today at 8:00 a.m. Eastern Time","length":59,"tagName":"p"},{"type":"text","content":"PRINCETON, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a clinical and corporate update and reported financial results for the first quarter ended March 31, 2025.","length":358,"tagName":"p"},{"type":"text","content":"“The first quarter of 2025 and recent weeks have been productive for PDS Biotech, highlighted by the initiation of our VERSATILE-003 Phase 3 clinical trial evaluating Versamune® HPV in recurrent/metastatic (“R/M”) HPV16-positive head and neck squamous carcinoma (“HNSCC”),” said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech. “We are pleased to announce that site activation is progressing, and that Mayo Clinic sites have recently been added to the trial. HPV16-positive HNSCC represents a large, rapidly growing patient population in need of targeted therapies to treat the underlying cause of the cancer, and our Versamune® HPV investigational therapy is currently the only targeted therapy in a Phase 3 trial specifically for HPV-16 positive tumors.”","length":790,"tagName":"p"},{"type":"text","content":"Clinical and Corporate Update","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"On April 23, 2025, the Company announced that three abstracts on ...